260 related articles for article (PubMed ID: 30706395)
21. Advancements in the design and scalable production of viral gene transfer vectors.
Sharon D; Kamen A
Biotechnol Bioeng; 2018 Jan; 115(1):25-40. PubMed ID: 28941274
[TBL] [Abstract][Full Text] [Related]
22. Enhanced antitumor effect of RGD fiber-modified adenovirus for gene therapy of oral cancer.
Dehari H; Ito Y; Nakamura T; Kobune M; Sasaki K; Yonekura N; Kohama G; Hamada H
Cancer Gene Ther; 2003 Jan; 10(1):75-85. PubMed ID: 12489031
[TBL] [Abstract][Full Text] [Related]
23. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications.
Hartman ZC; Appledorn DM; Amalfitano A
Virus Res; 2008 Mar; 132(1-2):1-14. PubMed ID: 18036698
[TBL] [Abstract][Full Text] [Related]
24. A novel system for the production of fully deleted adenovirus vectors that does not require helper adenovirus.
Cheshenko N; Krougliak N; Eisensmith RC; Krougliak VA
Gene Ther; 2001 Jun; 8(11):846-54. PubMed ID: 11423932
[TBL] [Abstract][Full Text] [Related]
25. Modulation of Starling forces and muscle fiber maturity permits adenovirus-mediated gene transfer to adult dystrophic (mdx) mice by the intravascular route.
Cho WK; Ebihara S; Nalbantoglu J; Gilbert R; Massie B; Holland P; Karpati G; Petrof BJ
Hum Gene Ther; 2000 Mar; 11(5):701-14. PubMed ID: 10757350
[TBL] [Abstract][Full Text] [Related]
26. Recombinant adenovirus vectors for gene therapy and clinical trials.
Nász I; Adám E
Acta Microbiol Immunol Hung; 2001; 48(3-4):323-48. PubMed ID: 11791337
[TBL] [Abstract][Full Text] [Related]
27. Adenovirus vectors for renal-targeted gene delivery.
Appledorn DM; Seregin S; Amalfitano A
Contrib Nephrol; 2008; 159():47-62. PubMed ID: 18391584
[TBL] [Abstract][Full Text] [Related]
28. An efficient and scalable process for helper-dependent adenoviral vector production using polyethylenimine-adenofection.
Dormond E; Meneses-Acosta A; Jacob D; Durocher Y; Gilbert R; Perrier M; Kamen A
Biotechnol Bioeng; 2009 Feb; 102(3):800-10. PubMed ID: 18821637
[TBL] [Abstract][Full Text] [Related]
29. Scaleable production of adenoviral vectors by transfection of adherent PER.C6 cells.
Subramanian S; Kim JJ; Harding F; Altaras GM; Aunins JG; Zhou W
Biotechnol Prog; 2007; 23(5):1210-7. PubMed ID: 17715941
[TBL] [Abstract][Full Text] [Related]
30. Rescue, amplification, and large-scale production of helper-dependent adenoviral vectors.
Palmer DJ; Ng P
Cold Spring Harb Protoc; 2011 Jul; 2011(7):857-66. PubMed ID: 21724821
[No Abstract] [Full Text] [Related]
31. Significance of Preexisting Vector Immunity and Activation of Innate Responses for Adenoviral Vector-Based Therapy.
Wang WC; Sayedahmed EE; Mittal SK
Viruses; 2022 Dec; 14(12):. PubMed ID: 36560730
[TBL] [Abstract][Full Text] [Related]
32. [Producing Ad-IFN gamma by suspension culture of HEK293 cells in a disposable bioreactor].
Wu Q; Huang W
Sheng Wu Gong Cheng Xue Bao; 2014 Nov; 30(11):1786-90. PubMed ID: 25985530
[TBL] [Abstract][Full Text] [Related]
33. Effective gene transfer to human melanomas via integrin-targeted adenoviral vectors.
Nakamura T; Sato K; Hamada H
Hum Gene Ther; 2002 Mar; 13(5):613-26. PubMed ID: 11916485
[TBL] [Abstract][Full Text] [Related]
34. The current status of adenovirus-based cancer gene therapy.
Shirakawa T
Mol Cells; 2008 Jun; 25(4):462-6. PubMed ID: 18460898
[TBL] [Abstract][Full Text] [Related]
35. Influence of culture passages on growth kinetics and adenovirus vector production for gene therapy in monolayer and suspension cultures of HEK 293 cells.
Park MT; Lee MS; Kim SH; Jo EC; Lee GM
Appl Microbiol Biotechnol; 2004 Oct; 65(5):553-8. PubMed ID: 15168091
[TBL] [Abstract][Full Text] [Related]
36. Molecular design for recombinant adeno-associated virus (rAAV) vector production.
Aponte-Ubillus JJ; Barajas D; Peltier J; Bardliving C; Shamlou P; Gold D
Appl Microbiol Biotechnol; 2018 Feb; 102(3):1045-1054. PubMed ID: 29204900
[TBL] [Abstract][Full Text] [Related]
37. In the rat liver, Adenoviral gene transfer efficiency is comparable to AAV.
Montenegro-Miranda PS; Pichard V; Aubert D; Ten Bloemendaal L; Duijst S; de Waart DR; Ferry N; Bosma PJ
Gene Ther; 2014 Feb; 21(2):168-74. PubMed ID: 24285217
[TBL] [Abstract][Full Text] [Related]
38. Adenovirus vector-based vaccine for infectious diseases.
Sakurai F; Tachibana M; Mizuguchi H
Drug Metab Pharmacokinet; 2022 Feb; 42():100432. PubMed ID: 34974335
[TBL] [Abstract][Full Text] [Related]
39. Development and optimization of an adenovirus production process.
Kamen A; Henry O
J Gene Med; 2004 Feb; 6 Suppl 1():S184-92. PubMed ID: 14978761
[TBL] [Abstract][Full Text] [Related]
40. Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions.
Lowenstein PR; Mandel RJ; Xiong WD; Kroeger K; Castro MG
Curr Gene Ther; 2007 Oct; 7(5):347-60. PubMed ID: 17979681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
